Abstract
Cancer gene therapy is a relatively new modality that might ultimately revolutionize oncology. The basic principle is to alter the tumor genetically to enhance more traditional chemo- and radiation therapy schema. The last decade has seen tremendous progress and development of new technologies in the areas of vector delivery, tumor targeting, and numerous clever ways to increase tumor killing, including early attempts to modulate tumor gene expression by RNA interference. In recent years, attempts to image affected cells have also been part of these efforts. Many studies have proceeded to the preclinical stage and a fair number to early clinical testing with some showing encouraging results. However, real impact on patient survival remains to be seen. One major problem still to be overcome is the quantitative delivery of the vector into the tumor mass. The next decade is expected to resolve many of these technical issues and improve the treatment of patients. This chapter will discuss new technologies and provide a brief overview of the field.
Chapter PDF
Similar content being viewed by others
Keywords
- Gene Therapy
- Severe Acute Respiratory Syndrome
- Therapeutic Gene
- Severe Acute Respiratory Syndrome
- Suicide Gene
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Alemany R (2007) Cancer selective adenoviruses. Mol Aspects Med 28:42–58
Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355
Barton KN, Freytag SO, Nurushev T, Yoo S, Lu M, Yin FF, Li S, Movsas B, Kim JH, Brown SL (2007) A model for optimizing adenoviral delivery in human cancer gene therapy trials. Hum Gene Ther 18:562–572
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick, F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376
Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2:711–719
Chang KJ, Lee JG, Holcombe RF, Kuo J, Muthusamy R, Wu ML (2008) Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 5:107–111
Chiang CS, Hong JH, Wu YC, McBride WH, Dougherty GJ (2000) Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Ther 7:1172–1178
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. [See comments.] Science 256:1550–1552
Culver KW, Van Gilder J, Link CJ, Carlstrom T, Buroker T, Yuh W, Koch K, Schabold K, Doornbas S, Wetjen B et al (1994) Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 5:343–379
Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D et al (2005) Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 11:149–159
Dykxhoorn DM, Lieberman J (2006) Knocking down disease with siRNAs. Cell 126:231–235
Fisher PB (2005) Is mda-7/IL-24 a magic bullet for cancer? Cancer Res 65:0128–10138
Freytag SO, Kim JH, Brown SL, Barton K, Lu M, Chung M (2004) Gene therapy strategies to improve the effectiveness of cancer radiotherapy. Expert Opin Biol Ther 4:1757–1770
Freytag SO, Barton KN, Brown SL, Narra V, Zhang Y, Tyson D, Nall C, Lu M, Ajlouni M, Movsas B, Kim JH (2007a) Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 15:1600–1606
Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M et al (2007b) Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15:1016–1023
Glasgow JN, Everts M, Curiel DT (2006) Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 13:830–844
Hammond SM (2006) MicroRNAs as oncogenes. Curr Opin Genet Dev 16:4–9
Hutvagner G, Simard MJ (2008) Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 9:22–32
Inoue S, Shanker M, Miyahara R, Gopalan B, Patel S, Oida Y, Branch CD, Munshi A, Meyn RE, Andreeff M et al (2006) MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther 6:73–91
Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS, Rehemtulla A (1999) Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59:1417–1421
Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8:173–184
Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6:376–385
Kufe D, Weichselbaum R (2003) Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2:326–329
Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC et al (2005a) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11:944–951
Li C, Bowles DE, van Dyke T, Samulski RJ (2005b) Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther 12:913–925
Liu X, Fortin K, Mourelatos Z (2008) MicroRNAs: biogenesis and molecular functions. Brain Pathol 18:113–121
Lu Y, Dang H, Middleton B, Zhang Z, Washburn L, Stout DB, Campbell-Thompson M, Atkinson MA, Phelps M, Gambhir SS et al (2006) Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad Sci USA 103:11294–11299
Martin SE, Caplen NJ (2007) Applications of RNA interference in mammalian systems. Annu Rev Genomics Hum Genet 8:81–108
Mattes J, Yang M, Foster PS (2007) Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir Cell Mol Biol 36:8–12
Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS et al (2004) A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10:5747–5753
Ng P, Graham FL (2002) Construction of first-generation adenoviral vectors. Methods Mol Med 69:389–414
Ng P, Parks RJ, Graham FL (2002) Preparation of helper-dependent adenoviral vectors. Methods Mol Med 69:371–388
Nie S, Xing Y, Kim GJ, Simons JW (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9:257–288
Putral LN, Gu W, McMillan NA (2006) RNA interference for the treatment of cancer. Drug News Perspect 19:317–324
Rosenberg E, Hawkins W, Holmes M, Amir C, Schmidt-Ullrich RK, Lin PS, Valerie K (2002) Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int J Radiat Oncol Biol Phys 52:831–836
Roth JA (2006) Adenovirus p53 gene therapy. Expert Opin Biol Ther 6:55–61
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C et al (2004) TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22:592–601
Siddiqui F, Barton KN, Stricker HJ, Steyn PF, Larue SM, Karvelis KC, Sparks RB, Kim JH, Brown SL, Freytag SO (2007) Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. Hum Gene Ther 18:312–322
Ternovoi VV, Curiel DT, Smith BF, Siegal GP (2006) Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab Invest 86:748–766
Tong AW, Nemunaitis J, Su, D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K et al (2005) Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 11:160–172
Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE (1995) Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55:4808–4812
Tsai CH, Hong JH, Hsieh KF, Hsiao HW, Chuang WL, Lee CC, McBride WH, Chiang CS (2006) Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Ther 13:1082–1092
Valerie K (1999) Viral vectors for gene therapy. In: Wu-Pong S, Rojanasakul Y (eds) Biopharmaceutical drug design and development. Humana, Totowa, New Jersey, pp 69–105
Valerie K, Hawkins W, Farnsworth J, Schmidt-Ullrich R, Lin PS, Amir C, Feden J (2001) Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther 8:3–8
Zamore PD, Haley B (2005) Ribo-gnome: the big world of small RNAs. Science 309:1519–1524
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Valerie, K., Graves, P. (2009). Strategies of Gene Transfer and Silencing, and Technical Considerations. In: Molls, M., Vaupel, P., Nieder, C., Anscher, M. (eds) The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-74386-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-540-74386-6_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-74385-9
Online ISBN: 978-3-540-74386-6
eBook Packages: MedicineMedicine (R0)